By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Mycophenolate

Mycophenolate

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|632 words

Mycophenolate Drug Profile

What is Mycophenolate?

Mycophenolate is an immunosuppressive medication belonging to the class of drugs known as antimetabolites. It is primarily used to prevent organ rejection in patients who have received kidney, liver, or heart transplants. The medication works by suppressing the immune system’s activity to prevent it from attacking transplanted organs.

Uses

Mycophenolate has several approved medical uses:

  • Kidney transplant rejection prevention: The primary use is preventing rejection in kidney transplant recipients, typically used in combination with other immunosuppressive drugs.
  • Heart transplant rejection prevention: Used as part of immunosuppressive regimens to prevent cardiac transplant rejection.
  • Liver transplant rejection prevention: Helps prevent liver transplant rejection when combined with other immunosuppressive medications.
  • Autoimmune conditions: Sometimes prescribed off-label for certain autoimmune diseases such as lupus nephritis and myasthenia gravis.
  • Inflammatory bowel disease: Occasionally used in severe cases of Crohn’s disease or ulcerative colitis when other treatments have failed.

How it works

Mycophenolate works by blocking an enzyme called inosine monophosphate dehydrogenase, which is essential for the production of DNA in rapidly dividing cells. Since immune cells multiply quickly when responding to foreign substances, this medication specifically targets and suppresses immune system activity. By reducing the immune system’s ability to produce new lymphocytes, it helps prevent the rejection of transplanted organs.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Diarrhea and abdominal pain
  • Headache
  • Fatigue and weakness
  • Increased susceptibility to infections
  • Tremor
  • High blood pressure
  • Swelling in hands, feet, or ankles

Serious side effects to watch for:

  • Severe infections due to immune suppression
  • Increased risk of certain cancers, particularly skin cancer and lymphoma
  • Severe gastrointestinal bleeding or ulceration
  • Progressive multifocal leukoencephalopathy (rare brain infection)
  • Bone marrow suppression leading to low blood cell counts

Warnings and precautions

  • Pregnancy and fertility: Mycophenolate can cause birth defects and pregnancy loss. Women of childbearing age must use effective contraception during treatment and for six weeks after stopping the medication.
  • Infection risk: Patients are at increased risk of serious infections, including opportunistic infections, due to immune system suppression. Live vaccines should be avoided.
  • Cancer surveillance: Regular monitoring for skin cancer and other malignancies is essential, as the medication increases cancer risk.
  • Kidney function: Dosage adjustments may be necessary in patients with kidney impairment, and regular monitoring of kidney function is required.
  • Blood monitoring: Regular blood tests are necessary to monitor for bone marrow suppression and other potential complications.

Interactions

Mycophenolate has several important drug interactions:

  • Antacids containing aluminum or magnesium: Can reduce mycophenolate absorption and should be taken at least two hours apart.
  • Cholestyramine: Significantly reduces mycophenolate levels by interrupting its circulation in the body.
  • Acyclovir and ganciclovir: May increase levels of both drugs, requiring dose monitoring.
  • Proton pump inhibitors: Can reduce mycophenolate absorption, potentially decreasing effectiveness.
  • Live vaccines: Should be avoided due to increased risk of infection from the vaccine.
  • Azathioprine: Should not be used together due to increased risk of bone marrow suppression.
  • Iron supplements: May reduce mycophenolate absorption when taken simultaneously.
  • Rifampin: Can significantly reduce mycophenolate levels, potentially leading to treatment failure.

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosages vary depending on the condition being treated and the specific formulation used. For kidney transplant patients, the usual dose ranges from 1 to 1.5 grams twice daily. Heart and liver transplant patients may receive 1.5 grams twice daily. The medication is available in both immediate-release and delayed-release formulations, which are not interchangeable. Dosages must be individualized based on patient response, tolerance, and concurrent medications. All dosing decisions should be made by a qualified healthcare provider who will consider the patient’s specific medical situation, kidney function, and other factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Mycophenolate." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/mycophenolate/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Iron supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Tamsulosin

By
Prof. Giorgi Pkhakadze
02/06/2026

Allopurinol

By
Prof. Giorgi Pkhakadze
02/06/2026

Domperidone

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up